Filing Flows › UroGen Pharma (URGN) › Q2 2026 › vs Q1 2026
UroGen Pharma (URGN) Q2 2026 vs Q1 2026 (quarter over quarter)
UroGen Pharma's revenue rose $21.5M (+42%) from $51.0M in Q1 2026 to $72.5M in Q2 2026. The biggest changes: Zusduri +$21.2M (+72%); Jelmyto +$315K (+1%).
UroGen Pharma, Q2 2026: revenue $72.5M (+199% year over year), operating margin 0.2%, net loss $14.4M, operating cash flow −$33.0M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Zusduri | $50.4M | $29.2M | $21.2M | +72% |
| Jelmyto | $22.0M | $21.7M | $315K | +1% |
| Revenue | $72.5M | $51.0M | $21.5M | +42% |
| Net loss | $14.4M | $23.6M | −$9.2M | -39% |
| Costs & expenses | $86.8M | $79.3M | $7.5M | +9% |
| Operating costs | $72.3M | $71.2M | $1.1M | +2% |
| Interest & other, net | $8.8M | $8.1M | $750K | +9% |
| Income tax | $5.6M | −$4.8M | $10.4M | — |
| Cost of revenue | $6.6M | $4.1M | $2.4M | +59% |
| Research & development | $17.3M | $15.6M | $1.7M | +11% |
| SG&A | $48.4M | $51.5M | −$3.0M | -6% |
| Operating cash sources | $38.4M | $50.0M | −$11.6M | -23% |
| Depreciation & amortization | $100K | $75K | $25K | +33% |
| Share-based compensation | $5.3M | $4.6M | $704K | +15% |
| Cash used in operations | $33.0M | $45.3M | −$12.3M | -27% |
| Net loss absorbed | $14.4M | $23.6M | −$9.2M | -39% |
| Working capital & other | $24.1M | $26.4M | −$2.4M | -9% |
Questions
How much did UroGen Pharma's revenue grow quarter over quarter in Q2 2026?
UroGen Pharma's revenue rose $21.5M (+42%) from $51.0M in Q1 2026 to $72.5M in Q2 2026.
What drove UroGen Pharma's revenue change in Q2 2026?
Zusduri +$21.2M (+72%); Jelmyto +$315K (+1%).